Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 1/2 1

Status

Completed 3Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1CNS 1

Conditions

Neurofibromatosis 1 1Neurofibroma, Plexiform 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Pharmacokinetics × Clear all
NCT02120222 2023-04-04

KPT-330

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
9 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT00323323 2017-01-20

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡